[Clinical evaluation of the therapeutic activity of the beta-pyridyl-carbinolic ester of clofibric acid].
D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000378:metabolism; D002784:Cholesterol / Q000378:metabolism; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D050356:Lipid Metabolism; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000378:metabolism; D011725:Pyridines / Q000627:therapeutic use*; D014280:Triglycerides / Q000378:metabolism; D014527:Uric Acid / Q000378:metabolism; D014665:Vasodilator Agents / Q000627:therapeutic use*
D010743:Phospholipids; D011725:Pyridines; D014280:Triglycerides; D014665:Vasodilator Agents; D014527:Uric Acid; D002784:Cholesterol; D002994:Clofibrate
Valutazione clinica dell'attività terapeutica dell'estere beta-piridil-carbinolico dell'ac. clofibrico.